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 Abstract 
A medicinal chemistry exploration of the human phosphodiesterase 4 (hPDE4) inhibitor cilomilast (1) was 
undertaken in order to identify inhibitors of phosphodiesterase B1 of Trypanosoma brucei (TbrPDEB1). T. 
brucei is the parasite which causes African sleeping sickness, a neglected tropical disease that affects 
thousands each year, and TbrPDEB1 has been shown to be an essential target of therapeutic relevance. 
Noting that 1 is a weak inhibitor of TbrPDEB1, we report the design and synthesis of analogs of this 
compound, culminating in 12b, a sub-micromolar inhibitor of TbrPDEB1 that shows modest inhibition of T. 
brucei proliferation. 
 
Neglected tropical diseases (NTDs) are a group of pathologies that mainly affect the poor in the developing 
world. The World Health Organization has defined 17 different NTDs, and this list includes human African 
trypanosomiasis (HAT), or sleeping sickness, which is a parasitic disease caused by the protozoan parasite 
Trypanosoma brucei. Currently, 50 million people are at risk within rural sub-Saharan Africa and the 
estimated incidence is around 10,000 cases a year.1   Melarsoprol and eflornithine, the current front-line 
therapies for advanced HAT, have been the drugs of choice for the treatment of second stage HAT. Though 
effective, these drugs are limited by serious and sometimes lethal side effects, inconvenient route of 
administration and increasing incidence of drug resistance. Though new efforts have produced new 
combination therapies (such as nifurtimox/eflornithine combination therapy (NECT)),2 further work is needed 
to develop the next generation of therapies that are safe, effective, and inexpensive. With this in mind, our 
research efforts are focused on repurposing established classes of agents that inhibit druggable human 
targets.3 
Phosphodiesterases (PDEs) are one such target; a family of enzymes that inactivate the cellular signaling 
agents cAMP or cGMP. In recent years it was shown that cAMP plays a key role in T. brucei biology. T. 
brucei expresses ﬁve cAMP-speciﬁc PDEs, two of which (TbrPDEB1 and TbrPDEB2) have been shown to 
be together essential for parasite proliferation by both RNAi and small molecules.4, 5 Initial screening and 
 early optimization experiments have uncovered a susceptibility of TbrPDEB1 and B2 to human PDE4 
(hPDE4) inhibitor chemotypes, and that the inhibition of these enzymes leads to parasite death in vitro. For 
example, we showed that piclamilast (2, Figure 1), a hPDE4 inhibitor, inhibited TbrPDEB1 and B2 (IC50 4.7 
and 11.4 μM, respectively), which translated to inhibition of T. brucei brucei (Tbb) cell growth (EC50= 9.6 
μM).5 At the same time, others identified 3 as a potent TbrPDE inhibitor via a high-throughput screening 
campaign.6 This racemic compound remains the most potent TbrPDE inhibitor described to date, despite 
several further reports.7-9 A key limitation of all the TbrPDEB inhibitors identified to date is the lack of 
selectivity over hPDE4, which is likely to lead to various characteristic PDE4 side effects, such as nausea 
and emesis. 
We were surprised at the divergence in TbrPDEB1 activity between closely related hPDE4 inhibitors: 
roflumilast (4) a close analog of 2, was completely inactive.5 Thus, for the purpose of studying a wider variety 
of hPDE4 inhibitors as starting points for TbrPDEB inhibitors, we investigated cilomiliast, 1, a related hPDE4 
inhibitor. Compound 1 (Ariflo, SB-207,499) is an orally active and selective hPDE4 inhibitor developed by 
GlaxoSmithKline for the treatment of respiratory disorders such as chronic obstructive pulmonary disease 
(COPD).10, 11 This compound has a reported IC50 of 84 nM against hPDE4B,12 and we observed an IC50 
against TbrPDEB1 of 16.4 μM. Given the prior art of repurposing hPDE4 inhibitors for TbrPDEB1, we felt that 
this result warranted additional medicinal chemistry explorations for trypanosomal PDE inhibitors. 
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Figure 1. The structure of 1, highlighting the tail (red) and head region (blue) explored in this work. Also 
shown are other hPDE4 inhibitors previously studied as inhibitors of TbrPDEB1.5, 6 Human PDE4 data shown 
is from previous reports.13, 14 
 
Our investigation into the SAR of 1 as a TbrPDEB1 inhibitor involved first assessing the relative 
stereochemistry of the headgroup (Figure 1, blue), as well as the importance of the carboxylate functionality. 
We also wished to determine whether a stereochemically simplified headgroup replacement could be 
achieved. Secondly, a key structural feature of the TbrPDEB1 binding site, predicted by homology modeling 
and confirmed by crystallography,5, 15 is a pocket adjacent to the binding site (termed the “parasite-“ or “P-
pocket”) that is deeper in comparison to the same region in hPDE4. Thus, guided by the SAR studies of the 
catechol diethers 2 and 3 reported previously that were intended to explore the “parasite pocket” of the 
enzyme, we now report exploration of the cyclopentyl ether (Figure 1, red) to longer, chain-extended 
versions, and we then studied the protein-ligand interactions in silico by carrying out molecular docking using 
the recently published crystal structure of TbrPDEB1.15 
 Initial analogues 5-8 (where R1=cyclopentyl) were prepared by the procedure shown in Scheme 1, based on 
the previously published preparation for 1.11 Analogs where R1=benzyl were synthesized using an analogous 
route (see Supporting Information). In the interest of exploring simplified headgroup replacements, 
piperidine analogues were also synthesized (Scheme S2, Supporting Information). 
We opted to first test compounds at 10 μM concentrations; those that were above 50% inhibition at this 
concentration were subjected to dose-response experiments. We have previously noted similarity between 
compound activity against TbrPDEB1 and B2. Thus, for efficiency, we focused our first round of compound 
assays on TbrPDEB1, and assumed similar (within 2-3 fold activity) against TbrPDEB2.  
While compound 1 is a 16.4 µM inhibitor of TbrPDEB1, the esters 5a and 5b were below the minimum 
percent inhibition cutoff to obtain an IC50 (Table 1). This is consistent with the SAR for hPDE4 previously 
reported.11 The benzyl analogue of cilomilast (compound 7) inhibits TbrPDEB1 with activity similar to 1, 
though it retains some potency against hPDE4 (IC50=0.54 µM). Notably, the compounds with a cis-orientation 
of the cyano and carboxylate groups are consistently more potent (compare 1 and 7 with 8a and 8b). 
Replacement of the cyclohexane headgroup with a piperidine ring resulted in significant loss of activity 
(Table S3, Supporting Information). Others have shown that preparation of analogs with catechol 
substituents that project into the P-pocket (c.f. 3) can lead to improved potency and selectivity.6, 7 We 
assumed that our catechol-derived analogs bind in a similar orientation as 2 and 3, and used this hypothesis 
to design analogs of 7. Thus, we replaced the phenyl group with three pyridine isomers (10a-c). As shown in 
Scheme 2, ester 5b was debenzylated using catalytic hydrogenation to provide phenol 9. This could be 
alkylated with the appropriate bromomethylpyridine, providing 10a-c following basic hydrolysis. These 
compounds were much less active (Table 2), and one (10b) was not soluble enough in the assay conditions 
to obtain inhibition data. 
 
 
 Scheme 1.a  
 
aReagents and conditions: (a) LiOH, H2O, MeOH, THF, rt, 2 h. 
We then prepared chain extended analogs of 7 by alkylation of 9 using various dibromoalkanes to provide 
the bromides 11, which could be utilized to alkylate a range of phenols. This provided analogs 12 after 
hydrolysis. (The synthesis and characterization of 13, the ester of precursor to 16a is included in the 
Supporting Information). 
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 The direct analog of 3 (12a) showed an approximate two-fold improvement over 1 (IC50=7.9 μM Table 2). 
The unadorned phenyl analog (12b), with the same spacer length as 12a, was more than 17-fold more 
potent than 1. Alteration of the chain length (12c and 12d) led to loss in potency, leading to compounds 
approximately equipotent to 1. Compound 12b (IC50 of 0.95 µM) is the most active compound in the series to 
date, being 17 times more active than 1 against TbrPDEB1, though it is 25-fold more potent against hPDE4 
(IC50=0.038 µM). This represents a selectivity improvement over 1 (which is 182-fold more potent against 
hPDE4 than TbrPDEB1). 
Exploration of para-substitution of the phenyl group with a range of electron donating, withdrawing, and 
neutral substituents resulted in loss of potency (12e-h).  
To determine whether compounds 1 and 12b had effects in T. brucei growth, we tested these for dose-
response using an Alamar blue cell viability assay,16 and found that, while neither compound inhibited growth 
of mammalian cells (NIH 3T3, TC50 >50 μM), we observed weak activity for 12b (EC50 = 26 μM) in T. brucei 
cellular assays. Compound 1 showed no effect upon T. brucei growth (EC50 > 50 μM). This is surprising, 
given the close concordance we and others observed between TbrPDEB1 enzyme inhibition and cellular 
growth inhibition with compounds 2 and 3.5, 6 
We considered two possible explanations for the lack of cellular activity. First, the essentiality of both 
TbrPDEB1 and B2 were demonstrated, as simultaneous knockdown by RNAi was required in order to impact 
on cellular proliferation.4 We have previously shown that inhibitors have a similar inhibitory profile when 
tested against both TbrPDEB1 and B2,5 which is perhaps not unexpected given the high sequence similarity 
in the binding site, and, based on this, we have been screening only against TbrPDEB1. In order to rule out 
the possible situation where 12b inhibits only TbrPDEB1, allowing a compensatory effect from TbrPDEB2, 
we tested 12b against TbrPDEB2, and observed anIC50 of 2.1 µM, which is approximately equivalent to the 
activity against TbrPDEB1. 
A second possible explanation for the lack of cellular activity of 1 and 12b, despite the structural similarity 
between 1-3, and 12b, could be limited trypanosome cell permeability caused by the negatively charged 
 carboxylate anion.17 We anticipated that compound 13, the ester precursor of 12b would likely display 
improved cellular penetration and act as a prodrug in trypanosome cells. Though 11d is inactive (>100 µM) 
against TbrPDEB1 and B2, we observed activity in T. brucei cell cultures (EC50=9.8 µM), which is suggestive 
that the uncharged ester can permeate the parasite cells and be hydrolyzed to the active species (12b). 
We looked towards molecular modeling to help explain our observations. Two crystal structures have been 
published for 1: (i) a complex with hPDE4B (1XLX) and (ii) a complex with hPDE4D (1XOM).18 The latter 
crystal structure, with a higher resolution, displays two possible binding modes for the bound ligand where 
the cyclohexyl showed two alternative conformations (Supporting Information, Figure S1). The structural 
differences between the human and the parasite phosphodiesterase are important for repositioning the 
human enzyme inhibitor to a trypanosomal enzyme inhibitor. For this reason we compare the enzyme active 
sites in the TbrPDEB1 and hPDE4D crystal structures in the top panel of Figure 2.15  
The predicted conformation of 3 bound to TbrPDEB1, overlaid with 1 as observed in the crystal structure of a 
hPDE4D (1XOM) is shown in the Supporting Information, Figure S2. This overlay reveals similar 
interactions for the methoxy group of these two ligands with the glutamine residue in the back pocket 
(Gln874 in TbrPDEB1) and rationalized our efforts to explore the P-pocket of the enzyme by replacing the 
cyclopentyl of 1 with different groups able to fill the P-pocket. 
Docking (POSIT v.1.0.2., OpenEye Scientific Software, Santa Fe, NM) was used to rationalize the results 
explained above. Firstly, we observe that the compounds with a cis- orientation of the cyano and carboxylate 
functionality are more potent than the trans-isomers. This can be explained by the observation that, in the 
cis-isomer, the cyano group is predicted to occupy an area at the entrance of the active site and the 
carboxylate group is in close contact with the magnesium ion (Figure 2A). The carboxylate group is in fact 
predicted to interact with this metal, explaining the loss of potency resulting from the removal or substitution 
of this group with an ester, leading to loss of a predicted electrostatic interaction. Following docking, the 
distal phenyl group of compound 12b is optimally placed in the P-pocket of the enzyme, as shown in Figure 
2B. The phenyl ring packs against two methionine residues and a tyrosine residue, and, in addition, there is 
 possibly a weak hydrogen bond between the C-alpha hydrogen of Gly873 and the oxygen atom of the 
phenoxy group of this ligand (Figure S3, Supporting Information).19 Visual inspection of the poses 
obtained by molecular docking confirms that the ideal linker connecting the two phenyl groups of the ligand 
contains four methylene groups, explaining the ~10-fold loss in potency observed for 12c and 12d. 
Substitutions in the para position of the distal phenyl group of 12b do not increase potency (Table 2). 
Modeling suggests that a small polar substituent in para position could have been tolerated by interacting 
with the hydroxyl group of Tyr845, and there was a strong rationale for introducing the tetrazole-containing 
substituent (12a) given the good potency of compound 3. However the, inconsistencies in the SAR between 
these two series may be rationalized by slight differences in binding conformation, leading to differences in 
positioning of the P-pocket substituents (see e.g. Figure S2).  
Finally, the 1000-fold higher activity of 3 over the matched analog 12a is clearly due to the bicyclic 
headgroup; the cycloheptyl N-substituent in this compound is predicted to fill the pocket in the entrance of 
the active site much better than the cyclohexyl system of cilomilast derivatives (Figure S2, Supporting 
Information). Further, the substituted bicyclic ring system is predicted to give increased lipophilic 
interactions with apolar side chains (such as a methionine and two phenylalanine residues). In our docked 
pose, the carbonyl group of the ligand is predicted to interact with the magnesium ion. 
In summary, we have identified a hPDE4 inhibitor chemotype that can be repurposed to discover new 
inhibitors of TbrPDEB1, one of which shows sub-micromolar activity toward TbrPDEB1 and a modest cellular 
growth inhibition of T. brucei. As with other repurposed hPDE4 chemotypes, however, we are faced with a 
formidable barrier of selectivity over hPDE4 which we have yet to surmount. On the other hand, nonetheless, 
we have shown an ability to improve compound potency within this chemotype, and this knowledge will be 
useful in informing other PDE inhibitor repurposing programs that are continuing. 
 
  
Figure 2. (A). The docked conformation of 1 (green carbon atoms) in TbrPDEB1 (4I15, gold carbon atoms) 
overlaid with one of the two bound conformations of the same ligand reported in the crystal structure of the 
human PDE4D-1 complex (1XOM, cyan). Amino acid side chain differences are shown as sticks. TbrPDEB1 
residue numbering is used, with the corresponding hPDE4D residues in brackets. The interactions of the 
ligand with Gln 874 and the Mg2+ ion are displayed in blue dashed lines. (B). Docked conformation of 12b in 
TbrPDEB1. The surface of the active site and the P-pocket are shown. Mg2+and Zn2+ are shown as green 
and grey spheres respectively. Two residues defining the P-pocket (Met868 and Tyr845) are also shown in 
sticks. In both figures, Mg2+and Zn2+ ions in the active site are shown as green and grey spheres 
respectively. Images were generated using PyMol (version 1.5.0.4, Schrodinger).  
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Compound syntheses and a tabulation of the compounds with their Northeastern registry numbers and 
screening data is available in the Supporting Information. The screening data has been made freely available 
as a shared data set at www.collaborativedrugdiscovery.com. Also included are biological assay and 
molecular modeling details. This Supporting Information is available free of charge via the Internet at 
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 Tables
Table 1. Cilomilast analogs tested against TbrPDEB1 
CN
R1
R2
O
R
MeO  
Cmpd R R1 R2 TbrPDEB1 
(%)a 
TbrPDEB1 IC50b 
(µM) 
1 
 
COOH H  16 ± 6.65  
5a 
 
COOCH3 H 31 ± 8  
5b 
 
COOCH3 H 40 ± 14  
8a 
 
H COOH 9.3 ± 9.3  
8b 
 
H COOH 20 ± 4.3  
6a 
 
H COOCH3 26 ± 3.6  
6b 
 
H COOCH3 28 ± 8.9  
7 
 
COOH H 77 ± 6.4 12 ± 1.18 
 
aInhibitor concentration 10.0 µM, tested in at least two independent replicate experiments all error was within 15%. 
bTested in at least two independent replicate experiments.  
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Table 2. Cilomilast analogs tested against TbrPDEB1 varying catechol substituents. 
CN
H
O
R
MeO
O
OH
 
Cmpd R 
TbrPDEB1 
(%)a 
TbrPDEB1 IC50c 
(µM) 
1 Cyclopentyl  16.4 ± 6.7 
10a 
N
 
33±12  
10b 
N
 
ndb  
10c N
 
11 ± 4.4  
12a 
O
N
HN
N N  
69 ± 1.4 7.9 ± 4.63 
12b 
O
 
96 ± 0.66c 0.95 ±0.14 
12c 
O
 
66 ± 2.2 11.0 ± 0.13 
12d 
O
 
54 ± 8 9.8 ± 1.27 
12e 
O
NC  
87 ± 12 3.6  ± 0.3 
12f 
O
O  
79  ±  3.4 3.5 ± 0.41 
12g 
O
 
74 ± 1.7 4.9 ± 2.81 
12h 
O
F  
79 ± 0.42c 9.2 ± 5.1 
aInhibitor concentration 10.0 µM, tested in at least two independent replicate experiments, all error was within 15%; 
bnd=no data due to insufficient solubility in the assay conditions. cTested in at least two independent replicate 
experiments. 
  
